West Pharmaceutical Services (NYSE:WST) Receives Daily Coverage Optimism Score of 0.16
News stories about West Pharmaceutical Services (NYSE:WST) have been trending somewhat positive on Friday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. West Pharmaceutical Services earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 46.3427211010168 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
WST has been the subject of several analyst reports. Zacks Investment Research lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Jefferies Group LLC restated a “hold” rating and set a $90.00 price target (up from $82.00) on shares of West Pharmaceutical Services in a research report on Friday, April 28th. Finally, BidaskClub lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $90.18.
West Pharmaceutical Services (NYSE:WST) traded up 0.28% on Friday, hitting $84.93. The stock had a trading volume of 250,059 shares. The company’s 50-day moving average price is $91.94 and its 200 day moving average price is $88.80. West Pharmaceutical Services has a one year low of $70.17 and a one year high of $99.91. The firm has a market cap of $6.28 billion, a price-to-earnings ratio of 36.45 and a beta of 1.10.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The company had revenue of $397.60 million during the quarter, compared to analysts’ expectations of $406 million. During the same period in the previous year, the company earned $0.59 EPS. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. Analysts expect that West Pharmaceutical Services will post $2.69 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be paid a dividend of $0.14 per share. The ex-dividend date is Tuesday, October 17th. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a dividend yield of 0.66%. West Pharmaceutical Services’s payout ratio is currently 22.22%.
In related news, CFO William J. Federici sold 54,996 shares of the company’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $95.45, for a total transaction of $5,249,368.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is owned by insiders.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.